Ignite Creation Date:
2024-05-06 @ 10:08 AM
Last Modification Date:
2024-10-26 @ 12:25 PM
Study NCT ID:
NCT03178591
Status:
COMPLETED
Last Update Posted:
2018-07-19
First Post:
2017-01-09
Brief Title:
Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor
Sponsor:
Chiang Mai University
Organization:
Chiang Mai University
Study Overview
Official Title:
Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor on Ischemic Burden in Stable Ischemic Heart Disease Patients
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Type 2 diabetes mellitus type 2 DM is an important disease with increasing prevalence worldwide More than 60 of diabetes patients die of CVD Diabetes is associated with 2-to 4- fold increase in the risk of coronary artery disease CAD Diabetes patients with stable ischemic heart disease may have more prevalent of asymptomatic ischemia or silent ischemia due to autonomic neuropathy Therefore detection of total myocardial ischemia including both symptomatic and silent ischemia using ambulatory electrocardiogram monitoring may provide better accuracy in ischemic burden and prognosis in diabetes patients DDP-4 inhibitors have favorable effects on atherosclerotic risk factors beyond glycemic control Furthermore DPP-4 inhibitors may have favorable effects on ischemic preconditioning in patients with CAD For this study we aim to compare the effects of between vildagliptin and Dapagliflozin on ischemic burden defined by total ischemic time markers of autonomic function biomarkers of myocardial injury and biomarkers of inflammation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None